HDAC9 and ovarian cancer: Our previously published matrix drug screen tested a library of 1912 compounds crossed with the SM birinapant and found that the class of HDAC inhibitors (entinostat, panobinostat, vorinostat, romidepsin, and Trichostatin A) are highly synergistic in killing ovarian cancer cells [11].